Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&J

Plus, news on the Immunome-Atreca asset deal, Nestlé buying CDX-7108 from Codexis, Oncternal, Visiox and more.

Immunome acquires Atreca antibody assets: Immunome will purchase antibody-related “assets and materials” from Atreca for $5.5 million upfront and another $7 million in potential development milestones. In a statement, CEO Clay Siegall said the agreement would expand the company’s “toolbox” and complement existing programs. — Katherine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Gonorrhea cases spike among young women in Europe, new study reveals

Gonorrhea cases have surged among young women in 15 European countries in 2022 and 2023, with a less significant increase observed among young men, highlighting

March 13, 2024

Black Americans more likely to trust medical information about prostate cancer from Black providers

Black Americans are 1.6 times more likely to believe medical information presented by a Black physician or patient as compared with information presented by a

July 19, 2023

New mindfulness therapy offers hope for teenagers struggling with depression

Researchers have developed a mindfulness therapy tailored specifically to appeal to teenagers to help them cope with increasing levels of depression and mental health problems.

November 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.